ObjectivesTo investigate differences in lung cancer (LC) management and survival using data from European population cancer registries.MethodsWe analysed 4,602 lung cancer cases diagnosed in 2010–2013, followed-up to 2019 in five countries. Multivariable logistic regression was used to calculate the Odds Ratio (OR) of surgery for stages I–II LC or chemo- or radiotherapy for stages III–IV LC. Relative survival (RS) was estimated by the actuarial method; Relative Excess Risk of death (RER), with 95% CI, was calculated by generalized linear models.ResultsDiagnostic work-up was extensive for 65.9% patients (range 57%, Estonia, Portugal - 85% (Belgium). Sixty-six percent of stages I–II patients underwent surgery; compared to non-operated, their adjusted OR decreased with age and was associated with main bronchus cancer (OR vs. lobes 0.25, CI, 0.08–0.82), stage II (OR vs. stage I: 0.42, CI, 0.29–0.60), comorbidity (OR vs. absent: 0.55, CI, 0.33–0.93), country (ORs: Estonia 1.82, CI, 1.28–2.60; Belgium 0.62, CI, 0.42–0.91; Portugal 0.69, CI, 0.52–0.93).Almost half of stages III–IV patients received chemo- or radiotherapy only; the adjusted OR vs. non receiving decreased with age and was associated with unspecified cancer topography or morphology. The adjusted five-year RER increased with age and stage and was lower for women (0.78, CI, 0.72–0.86), above the reference for main bronchus cancer (1.37, CI, 1.21–1.54) and unspecified morphology (1.17, CI, 1.05–1.30). Surgery carried the lowest mortality (RS 56.9; RER 0.13, CI, 0.11–0.15) with RER above the mean in Estonia (1.20, CI, 1.10–1.30), below it in Portugal (0.88, CI, 0.82–0.93) and Switzerland (0.91, CI, 0.84–0.99). Comorbidity (1.21, CI, 1.09–1.35) and not smoking (0.68, CI, 0.57–0.81) were associated with RER.ConclusionsThe survival benefit of early diagnosis, allowing curative surgery, was evident at the population level. Screening for subjects at risk and adhesion to standard care should be incremented across the EU by funding better equipment and training health personnel.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.